Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?

被引：0
|
作者：
Arulananda, Surein
John, Thomas
机构：
[1] Olivia Newton John Canc Res Inst, Canc Immunobiol Lab, Heidelberg, Vic, Australia
[2] Austin Hlth, Dept Med Oncol, Heidelberg, Vic, Australia
[3] La Trobe Univ, Sch Canc Med, Heidelberg, Vic, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 01期
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; OSIMERTINIB;
D O I：
10.1016/j.jtho.2019.10.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 14
页数：3
相关论文
共 50 条
  • [41] Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
    Kunimasa, Kei
    Nishino, Kazumi
    Sato, Yoshiharu
    Mori, Masahide
    Ihara, Shoichi
    Suzuki, Hidekazu
    Nagatomo, Izumi
    Kumagai, Toru
    Morishima, Toshitaka
    Imamura, Fumio
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [42] Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs
    Leonetti, Alessandro
    Capula, Mjriam
    Minari, Roberta
    Mazzaschi, Giulia
    Gregori, Alessandro
    El Hassouni, Btissame
    Papini, Filippo
    Bordi, Paola
    Verze, Michela
    Avan, Amir
    Tiseo, Marcello
    Giovannetti, Elisa
    CELLS, 2021, 10 (06)
  • [43] A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure
    Lam, T. C.
    Tsang, K.
    Choi, H.
    Lee, V. H. F.
    Lam, K. O.
    Chiang, C. L.
    So, T. H.
    Chan, W. W.
    Nyaw, S. F.
    Lim, F.
    Lau, J. O.
    Chik, J.
    Kong, S. F.
    Lee, A. W. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1389 - S1389
  • [44] Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients
    Hackner, Klaus
    Buder, Anna
    Hochmair, Maximilian J.
    Strieder, Matthaeus
    Grech, Christina
    Fabikan, Hannah
    Burghuber, Otto C.
    Errhalt, Peter
    Filipits, Martin
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2021, 15
  • [45] Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA
    Li, Y.
    Xu, Z.
    Wang, S.
    Zhu, Y.
    Ma, D.
    Mu, Y.
    Ying, J.
    Xing, P.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S445 - S445
  • [46] Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
    Baldacci, Simon
    Mazieres, Julien
    Tomasini, Pascale
    Girard, Nicolas
    Guisier, Florian
    Audigier-Valette, Clarisse
    Monnet, Isabelle
    Wislez, Marie
    Perol, Maurice
    Do, Pascal
    Dansin, Eric
    Leduc, Charlotte
    Leprieur, Etienne Giroux
    Moro-Sibilot, Denis
    Tulasne, David
    Kherrouche, Zoulika
    Labreuche, Julien
    Cortot, Alexis B.
    ONCOTARGET, 2017, 8 (62) : 105103 - 105114
  • [47] Socioeconomic Disparities and Overall Survival Differences Among Ethnic-Minority Patients with EGFR-Mutated NSCLC Treated with Osimertinib
    Lee, M.
    Miao, E.
    Zhang, C.
    Xue, X.
    Tuckman, S.
    Ohri, N.
    Halmos, B.
    Cheng, H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S192 - S194
  • [48] A retrospective analysis of locally advanced EGFR-mutated NSCLC patients with durvalumab after chemoradiotherapy
    Uchida, Yoshiyasu
    Ninomiya, Takashi
    Harada, Daijiro
    Kozuki, Toshiyuki
    ANNALS OF ONCOLOGY, 2022, 33 : S488 - S488
  • [49] Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib
    Wu, Chen-Te
    Hsu, Ping-Chih
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Wu, Chiao-En
    THORACIC CANCER, 2023, 14 (25) : 2548 - 2557
  • [50] Prognostic impact of bone metastases in osimertinib-treated patients with EGFR-mutated NSCLC
    Tanaka, Ichidai
    Gen, Soei
    Hori, Kazumi
    Morise, Masahiro
    Koyama, Junji
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Ishii, Makoto
    CANCER SCIENCE, 2025, 116 : 329 - 329
12345